REFERENCES - MCL
1. Adams J et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999;59:2615-2622.
2. Adams J et al. Proteasome inhibition: a new strategy in cancer treatment. Invest New Drugs. 2000;18:109-121.
3. Glickman MH et al. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev. 2002;82 (2):373-428.
4. Hideshima T et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001;61(7):3071-3076.
5. Rajkumar SV, Richardson PG, Hideshima T, et al. J Clin Oncol. 23:630-639;
6. Perez-Galan P, Roue G, Villamor N, et al. Blood. 2006; 107:257-264;
7. Chiarle R, Budel LM, Skolnik J, et al. Blood. 2000;95:619-626.
8. Leonard JP, Schattner EJ, Coleman M et al. Curr Opin Oncol. 2001;13:342-347;
9. Fisher RI, Miller TP, O'connor OA. Hematol. 2004:221-236.
10. Khouri IF, Lee MS, Saliba RM et al. Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol. 2003;21(23):4407-4412.
11. Fisher RI, Dahlberg S, Nathwani BN et al. A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study. Blood. 1995;85(4)1075-1082.
12. Hiddeman W, Unterhalt M, Herrmann R et al. Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German low-grade lymphoma study group. J Clin Oncol. 1998;16(5):1922-1930.
13. Armitage J, Weisenburger D. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. J Clin Oncol.1998;16(8): 2780-2795.
14. Data on file.
